Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial
- 1 November 2005
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 366 (9498), 1695-1703
- https://doi.org/10.1016/s0140-6736(05)67694-5
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Methicillin-ResistantStaphylococcus aureusDisease in Three CommunitiesNew England Journal of Medicine, 2005
- Antimicrobial interventions for the management of diabetic foot infectionsExpert Opinion on Pharmacotherapy, 2005
- Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infectionsJournal of Antimicrobial Chemotherapy, 2005
- Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving boneDiabetic Medicine, 2004
- Pé diabético: análise bacteriológica de 141 casosArchives of Endocrinology and Metabolism, 2004
- Ertapenem, the first of a new group of carbapenemsJournal of Antimicrobial Chemotherapy, 2003
- Erfahrungen im Umgang mit hochresistenten Keimen bei Patienten mit diabetischem Fuß-Syndrom unter besonderer Berücksichtigung von MRSA-InfektionenDeutsche Medizinische Wochenschrift (1946), 2001
- Piperacillin/Tazobactam Therapy for Diabetic Foot InfectionFoot & Ankle International, 1998
- Foot Infections in Diabetic Patients: The Role of AnaerobesClinical Infectious Diseases, 1995
- Algorithm AS 162: Multivariate Conditional Logistic Analysis of Stratum- Matched Case-Control StudiesJournal of the Royal Statistical Society Series C: Applied Statistics, 1981